688443 Stock Overview

A biopharmaceutical company, engages in the research and development, production, and sale of antibody drugs in China. More details

688443 fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	2/6
Past Performance	0/6
Financial Health	4/6
Dividends	0/6

Rewards

Revenue is forecast to grow 56.27% per year

Risk Analysis

Does not have meaningful revenue (CN¥14M)

Currently unprofitable and not forecast to become profitable over the next 3 years

My Notes

Capture your thoughts, links and company narrative

Chongqing Genrix Biopharmaceutical Co., Ltd. Competitors

Zhejiang Orient Gene Biotech

SHSE:688298

CN¥5.9b

Daan Gene

SZSE:002030

CN¥8.2b

Nanjing Vazyme Biotech

SHSE:688105

CN¥9.1b

Hangzhou Biotest BiotechLtd

SHSE:688767

CN¥3.3b

Price History & Performance

Summary of share price highs, lows and changes for Chongqing Genrix Biopharmaceutical
Historical stock prices
Current Share Price	CN¥26.25
52 Week High	CN¥36.40
52 Week Low	CN¥22.11
Beta	0
1 Month Change	-3.56%
3 Month Change	8.92%
1 Year Change	n/a
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	-21.24%

Recent updates

Shareholder Returns

	688443	CN Biotechs	CN Market
7D	-5.3%	-0.7%	0.4%
1Y	n/a	-18.4%	12.3%

Return vs Industry: Insufficient data to determine how 688443 performed against the CN Biotechs industry.

Return vs Market: Insufficient data to determine how 688443 performed against the CN Market.

Price Volatility

Is 688443's price volatile compared to industry and market?
688443 volatility
688443 Average Weekly Movement	10.9%
Biotechs Industry Average Movement	8.9%
Market Average Movement	8.8%
10% most volatile stocks in CN Market	13.0%
10% least volatile stocks in CN Market	5.8%

Stable Share Price: 688443 has not had significant price volatility in the past 3 months compared to the CN market.

Volatility Over Time: Insufficient data to determine 688443's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
2015	674	n/a	www.genrixbio.com

Chongqing Genrix Biopharmaceutical Co., Ltd., a biopharmaceutical company, engages in the research and development, production, and sale of antibody drugs in China. It develops GR1501, a monoclonal antibody for the treatment of axial spondylarthritis; GR1801, an anti-rabies virus G protein bispecific antibody; GR1802, an anti-IL-4Ra monoclonal antibody; GR1603, a monoclonal antibody for systemic lupus erythematosus; GR2002 an anti-TSLP bispecific antibody; WM1R3, a family receptor bispecific antibody; GR2001, a monoclonal antibody; GR2201, a monoclonal antibody for VZV infection; GR1803, a bispecific antibody for multiple myeloma; GR1901, a bispecific antibody; WM202 a bispecific antibody; WM215, a single-domain antibody; GR1401, an anti-EGFR monoclonal antibody; and GR1405 an anti-PD-L1 monoclonal antibody. The company was founded in 2015 and is based in Chongqing, China.

Chongqing Genrix Biopharmaceutical Co., Ltd. Fundamentals Summary

How do Chongqing Genrix Biopharmaceutical's earnings and revenue compare to its market cap?
688443 fundamental statistics
Market cap	CN¥9.63b
Earnings (TTM)	-CN¥779.42m
Revenue (TTM)	CN¥13.56m

709.8x

P/S Ratio

-12.3x

P/E Ratio

Is 688443 overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
688443 income statement (TTM)
Revenue	CN¥13.56m
Cost of Revenue	CN¥2.08m
Gross Profit	CN¥11.48m
Other Expenses	CN¥790.90m
Earnings	-CN¥779.42m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)	-2.13
Gross Margin	84.64%
Net Profit Margin	-5,747.82%
Debt/Equity Ratio	31.8%

How did 688443 perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2024/12/25 20:05
End of Day Share Price	2024/12/25 00:00
Earnings	2024/09/30
Annual Earnings	2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Chongqing Genrix Biopharmaceutical Co., Ltd. is covered by 8 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Peng Zou	China International Capital Corporation Limited
null null	China International Capital Corporation Limited
Ziyu He	China International Capital Corporation Limited